Supplemental Table 2.
Demographics of patients did not undergo any operations (n=189)
| Uterus (n=60) | Ovary (n=104) | Cervix (n=13) | Vulva/vagina (n=12) | Total (n=189) | |
|---|---|---|---|---|---|
| Age (y) | |||||
| 17–19 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 20–29 | 0 (0) | 5 (4.8) | 1 (7.7) | 0 (0) | 6 (3.2) |
| 30–39 | 3 (5.0) | 7 (6.7) | 1 (7.7) | 0 (0) | 11 (5.8) |
| 40–49 | 3 (5.0) | 19 (18.3) | 2 (15.4) | 0 (0) | 24 (12.7) |
| 50–59 | 13 (21.7) | 18 (17.3) | 3 (23.1) | 4 (33.3) | 38 (20.1) |
| 60–69 | 15 (25.0) | 27 (26.0) | 5 (38.5) | 2 (16.7) | 49 (25.9) |
| 70–79 | 12 (20.0) | 19 (18.3) | 1 (7.7) | 2 (16.7) | 34 (18.0) |
| 80–89 | 13 (21.7) | 9 (8.7) | 0 (0) | 4 (33.3) | 26 (13.8) |
| >90 | 1 (1.7) | 0 (0) | 0 (0) | 0 (0) | 1 (0.5) |
| Region | |||||
| Europe & Central Asia | 44 (73.3) | 64 (61.5) | 4 (30.8) | 11 (91.7) | 123 (65.1) |
| Latin America & Caribbean | 6 (10.0) | 6 (5.8) | 4 (30.8) | 1 (8.3) | 17 (9.0) |
| East Asia & Pacific | 0 (0) | 0 (0) | 3 (23.1) | 0 (0) | 3 (1.6) |
| South Asia | 1 (1.7) | 27 (26.0) | 0 (0) | 0 (0) | 28 (14.8) |
| North America | 5 (8.3) | 2 (1.9) | 0 (0) | 0 (0) | 7 (3.7) |
| Middle East & North Africa | 2 (3.3) | 5 (4.8) | 0 (0) | 0 (0) | 7 (3.7) |
| Sub-Saharan Africa | 2 (3.3) | 0 (0) | 2 (15.4) | 0 (0) | 4 (2.1) |
| Income group | |||||
| High | 49 (81.7) | 68 (65.4) | 4 (30.8) | 11 (91.7) | 132 (69.4) |
| Upper middle | 7 (11.7) | 6 (5.8) | 7 (53.9) | 1 (8.3) | 21 (11.1) |
| Low-middle | 4 (6.7) | 30 (28.9) | 2 (15.4) | 0 (0) | 36 (19.1) |
| BMI (kg/m2) | |||||
| <18.5 | 1 (1.7) | 3 (2.9) | 0 (0) | 0 (0) | 4 (2.1) |
| 18.5–24.9 | 14 (23.3) | 46 (44.2) | 6 (46.2) | 6 (50) | 72 (38.1) |
| 25–29.9 | 11 (18.3) | 30 (28.9) | 0 (0) | 2 (16.7) | 43 (22.8) |
| 30–34.9 | 13 (21.7) | 14 (13.5) | 5 (38.5) | 2 (16.7) | 34 (18.0) |
| 35–39.9 | 7 (11.7) | 4 (3.9) | 0 (0) | 1 (8.3) | 12 (6.4) |
| ≥40 | 11 (18.3) | 6 (5.8) | 2 (15.4) | 0 (0) | 19 (10.1) |
| Not available | 3 (5.0) | 1 (1.0) | 0 (0) | 1 (8.3) | 5 (2.7) |
| WHO Performance Status | |||||
| 0 | 20 (33.3) | 48 (46.2) | 7 (53.9) | 2 (16.7) | 77 (40.7) |
| 1 | 29 (48.3) | 37 (35.6) | 5 (38.5) | 8 (66.7) | 79 (41.8) |
| 2 | 9 (15.0) | 15 (14.4) | 1 (7.7) | 0 (0) | 25 (13.2) |
| 3 | 2 (3.3) | 2 (1.9) | 0 (0) | 0 (0) | 4 (2.1) |
| 4 | 0 (0) | 1 (1.0) | 0 (0) | 1 (8.3) | 2 (1.1) |
| Not available | 0 (0) | 1 (1.0) | 0 (0) | 1 (8.3) | 2 (1.1) |
| CCI | |||||
| 0 | 5 (8.3) | 31 (29.8) | 4 (30.8) | 0 (0) | 40 (21.2) |
| 1 | 9 (15.0) | 16 (15.4) | 1 (7.7) | 2 (16.7) | 28 (14.8) |
| 2 | 10 (16.7) | 24 (23.1) | 6 (46.2) | 3 (25.0) | 43 (22.8) |
| 3 | 12 (20.0) | 13 (12.5) | 1 (7.7) | 2 (16.7) | 28 (14.8) |
| 4 | 11 (18.3) | 13 (12.5) | 1 (7.7) | 2 (16.7) | 27 (14.3) |
| 5 | 5 (8.3) | 3 (2.9) | 0 (0) | 2 (16.7) | 10 (5.3) |
| 6 | 7 (11.7) | 4 (3.9) | 0 (0) | 1 (8.3) | 12 (6.4) |
| 7 | 1 (1.7) | 0 (0) | 0 (0) | 0 (0) | 1 (0.5) |
| ASA grade | |||||
| 1 | 6 (10.0) | 25 (24.0) | 4 (30.8) | 1 (8.3) | 36 (19.1) |
| 2 | 22 (36.7) | 57 (54.8) | 6 (46.2) | 6 (50.0) | 91 (48.2) |
| 3 | 28 (46.7) | 19 (18.3) | 3 (23.1) | 5 (41.7) | 55 (29.1) |
| 4 | 1 (1.7) | 2 (1.9) | 0 (0) | 0 (0) | 3 (1.6) |
| 5 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Not available | 3 (5.0) | 1 (1.0) | 0 (0) | 0 (0) | 4 (2.1) |
| FIGO stage | |||||
| Not cancer | 1 (1.7) | 5 (4.8) | 0 (0) | 3 (25.0) | 9 (4.8) |
| 1/2 | 45 (75.0) | 28 (26.9) | 12 (92.3) | 8 (66.7) | 93 (49.2) |
| 3/4 | 9 (15.0) | 70 (67.3) | 1 (7.7) | 1 (8.3) | 81 (42.9) |
| Not available | 5 (8.3) | 1 (1.0) | 0 (0) | 0 (0) | 6 (3.2) |
| Histology | |||||
| SCC | 0 (0) | 0 (0) | 13 (100.0) | 10 (83.3) | 23 (12.2) |
| Adenocarcinoma | 57 (95.0) | 86 (82.7) | 0 (0) | 0 (0) | 143 (75.7) |
| GCST | 0 (0) | 4 (3.9) | 0 (0) | 0 (0) | 4 (2.1) |
| Other | 2 (3.3) | 0 (0) | 0 (0) | 1 (8.3) | 3 (1.6) |
| Benign/preinvasive/borderline | 0 (0) | 4 (3.9) | 0 (0) | 1 (8.3) | 5 (2.7) |
| Not available | 1 (1.7) | 10 (9.6) | 0 (0) | 0 (0) | 11 (5.8) |
Data presented as total number (percentage) unless stated otherwise.
ASA grade, American Society of Anaesthesiologists Physical Status Classification system; BMI, body mass index; CCI, Charlson Comorbidity Index; FIGO, International Federation of Gynaecology and Obstetrics; GCST, germ cell, sex cord stromal or trophoblastic tumors; NACT, neoadjuvant chemotherapy; SCC, squamous cell carcinoma; WHO, World Health Organization.
Fotopoulou. Gynecologic cancer surgery during the COVID-19 pandemic. Am J Obstet Gynecol 2022.